Transcode Therapeutics, INC. (RNAZ) — SEC Filings

Overview

Transcode Therapeutics, INC. (RNAZ) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 7, 2026: On April 7, 2026, Transcode Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement and unregistered sales of equity securities. The filing also includes information on the creation of a direct financial obligation and Regulation FD disclosures. Specific details regarding th

Sentiment Summary

Across 50 filings, the sentiment breakdown is: 2 bullish, 5 bearish, 41 neutral, 2 mixed. The dominant filing sentiment for Transcode Therapeutics, INC. is neutral.

Filing Type Overview

Transcode Therapeutics, INC. (RNAZ) has filed 4 DEFA14A, 27 8-K, 4 8-K/A, 5 10-Q, 4 DEF 14A, 1 10-K/A, 1 10-K, 1 S-1, 1 SC 13G/A, 1 SC 13G, 1 SC 13D with the SEC between May 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (50)

• DEFA14A Filing — DEFA14A · Apr 7, 2026
• Transcode Therapeutics Files 8-K on Agreements and Equity Sales — 8-K · Apr 7, 2026 Risk: medium
  On April 7, 2026, Transcode Therapeutics, Inc. filed an 8-K report detailing a material definitive agreement and unregistered sales of equity securities. The fi
• Transcode Therapeutics Files 8-K Amendment — 8-K/A · Dec 23, 2025 Risk: low
  Transcode Therapeutics, Inc. filed an amendment (No. 3) to its Form 8-K on December 23, 2025, reporting events that occurred on October 8, 2025. The filing prim
• 8-K Filing — 8-K · Dec 22, 2025
• 8-K Filing — 8-K · Dec 11, 2025
• Transcode's Net Loss Nearly Doubles Amidst Warrant Revaluation, Strategic Acquisition — 10-Q · Nov 14, 2025 Risk: high
  Transcode Therapeutics, Inc. (RNAZ) reported a significant increase in net loss for the nine months ended September 30, 2025, reaching $(21,217,966) compared to
• Transcode Therapeutics Files 8-K — 8-K · Oct 27, 2025 Risk: low
  Transcode Therapeutics, Inc. filed an 8-K on October 27, 2025, reporting material modifications to the rights of security holders, amendments to its articles of
• Transcode Therapeutics Files 8-K/A Amendment — 8-K/A · Oct 17, 2025 Risk: low
  Transcode Therapeutics, Inc. filed an amendment (8-K/A) on October 17, 2025, to a previous report concerning a material definitive agreement. The original event
• Transcode Therapeutics Files 8-K — 8-K · Oct 14, 2025 Risk: low
  Transcode Therapeutics, Inc. filed an 8-K on October 14, 2025, reporting an event that occurred on October 13, 2025. The filing is primarily for "Other Events"
• Transcode Therapeutics Files 8-K Amendment — 8-K/A · Oct 8, 2025 Risk: low
  Transcode Therapeutics, Inc. filed an amendment (Amendment No. 1) to its Form 8-K on October 8, 2025. This amendment pertains to the entry into a material defin
• Transcode Therapeutics Enters Material Definitive Agreement — 8-K · Oct 3, 2025 Risk: medium
  On September 30, 2025, Transcode Therapeutics, Inc. entered into a material definitive agreement. The filing does not provide specific details about the agreeme
• Transcode Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · Sep 2, 2025 Risk: low
  Transcode Therapeutics, Inc. filed an 8-K on August 29, 2025, reporting on the submission of matters to a vote of security holders. The filing does not contain
• Transcode's Net Loss Widens to $16.36M Amid Warrant Revaluation — 10-Q · Aug 14, 2025 Risk: high
  Transcode Therapeutics, Inc. (RNAZ) reported a significant increase in net loss for the six months ended June 30, 2025, reaching $16,361,915, a substantial rise
• Transcode Therapeutics Seeks Shareholder Approval for Director Elections, Expanded Stock Plan — DEF 14A · Jul 15, 2025 Risk: medium
  Transcode Therapeutics, Inc. (RNAZ) is holding its 2025 Annual Meeting on August 29, 2025, to address several key proposals. The company plans to elect four dir
• Transcode Therapeutics Files 8-K on Shareholder Nominations — 8-K · Jun 13, 2025 Risk: medium
  Transcode Therapeutics, Inc. filed an 8-K on June 13, 2025, reporting shareholder nominations pursuant to Exchange Act Rule 14a-11. The filing date for the repo
• Transcode Therapeutics Q1 2025 10-Q Filed — 10-Q · May 14, 2025 Risk: medium
  Transcode Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company reported total assets of $1,029,095 and total liabilities of $2,33
• Transcode Therapeutics Faces Delisting Concerns — 8-K · May 7, 2025 Risk: high
  Transcode Therapeutics, Inc. filed an 8-K on May 7, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the e
• Transcode Therapeutics Files 8-K on Security Holder Rights — 8-K · May 5, 2025 Risk: medium
  Transcode Therapeutics, Inc. filed an 8-K on May 5, 2025, reporting material modifications to the rights of security holders and amendments to its articles of i
• Transcode Therapeutics Files 8-K — 8-K · May 2, 2025 Risk: low
  Transcode Therapeutics, Inc. filed an 8-K on May 2, 2025, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and financial
• Transcode Therapeutics Files 2024 Annual Report Amendment — 10-K/A · Apr 30, 2025 Risk: low
  Transcode Therapeutics, Inc. filed an amendment (10-K/A) to its annual report for the fiscal year ended December 31, 2024. The company, incorporated in Delaware
• Transcode Therapeutics Files 8-K — 8-K · Apr 21, 2025 Risk: low
  Transcode Therapeutics, Inc. filed an 8-K on April 21, 2025, reporting on matters submitted to a vote of security holders, other events, and financial statement
• TransCode Therapeutics Seeks Shareholder Approval for Reverse Stock Split — DEFA14A · Apr 16, 2025 Risk: medium
  TransCode Therapeutics, Inc. is holding a special meeting on April 21, 2025, to vote on a proposal to authorize a reverse stock split. The company is urging sha
• Transcode Therapeutics Files 2024 10-K — 10-K · Apr 15, 2025 Risk: medium
  Transcode Therapeutics, Inc. filed its 2024 10-K on April 15, 2025, reporting its financial position as of December 31, 2024. The company, based in Boston, MA,
• TransCode Therapeutics Files Definitive Proxy Statement — DEF 14A · Apr 11, 2025 Risk: low
  TransCode Therapeutics, Inc. filed its definitive proxy statement on April 11, 2025, for its annual meeting of stockholders. The filing outlines the proposals t
• Transcode Therapeutics Enters Material Definitive Agreement — 8-K · Mar 25, 2025 Risk: medium
  On March 23, 2025, Transcode Therapeutics, Inc. entered into a material definitive agreement. The company also reported other events and filed financial stateme
• Transcode Therapeutics Files 8-K — 8-K · Feb 25, 2025 Risk: low
  Transcode Therapeutics, Inc. filed an 8-K on February 25, 2025, reporting on the submission of matters to a vote of security holders, other events, and financia
• Transcode Therapeutics Files 8-K — 8-K · Feb 4, 2025 Risk: low
  Transcode Therapeutics, Inc. filed an 8-K on February 4, 2025, reporting on matters submitted to a vote of security holders, other events, and financial stateme
• Transcode Therapeutics Files Definitive Proxy Statement — DEF 14A · Dec 30, 2024 Risk: low
  Transcode Therapeutics, Inc. filed its definitive proxy statement (DEF 14A) on December 30, 2024, for its annual meeting of stockholders. The filing outlines th
• Transcode Therapeutics Files 8-K — 8-K · Dec 20, 2024 Risk: low
  Transcode Therapeutics, Inc. filed an 8-K on December 20, 2024, reporting an event that occurred on December 18, 2024. The filing pertains to "Other Events" and
• Transcode Therapeutics Files S-1 for Public Offering — S-1 · Dec 6, 2024 Risk: medium
  Transcode Therapeutics, Inc. filed an S-1 registration statement on December 6, 2024, to register an unspecified number of securities. The company, incorporated
• Transcode Therapeutics Files 8-K: Material Agreement & Equity Sales — 8-K · Dec 2, 2024 Risk: medium
  On November 26, 2024, Transcode Therapeutics, Inc. entered into a material definitive agreement, likely related to its business operations. The company also dis
• Transcode Therapeutics Files 8-K on Security Holder Rights — 8-K · Nov 29, 2024 Risk: medium
  Transcode Therapeutics, Inc. filed an 8-K on November 29, 2024, reporting a material modification to the rights of security holders and amendments to its articl
• Transcode Therapeutics Files 8-K on Shareholder Vote Matters — 8-K · Nov 25, 2024 Risk: low
  Transcode Therapeutics, Inc. filed an 8-K on November 25, 2024, reporting on matters submitted to a vote of security holders as of November 22, 2024. The filing
• Transcode Therapeutics Files Q3 2024 10-Q — 10-Q · Nov 14, 2024 Risk: medium
  Transcode Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results and provided updates on its busines
• TransCode Therapeutics Seeks Shareholder Approval for Reverse Stock Split — DEFA14A · Nov 13, 2024 Risk: medium
  TransCode Therapeutics, Inc. is holding a Special Meeting on November 22, 2024, where shareholders will vote on a proposal to authorize the Board of Directors t
• Transcode Therapeutics Faces Delisting Concerns — 8-K · Nov 6, 2024 Risk: high
  Transcode Therapeutics, Inc. filed an 8-K on November 6, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule. The company's pri
• SC 13G/A Filing — SC 13G/A · Nov 6, 2024
• TransCode Therapeutics Files Proxy Statement for Annual Meeting — DEF 14A · Oct 28, 2024 Risk: low
  TransCode Therapeutics, Inc. filed a definitive proxy statement (DEF 14A) on October 28, 2024, for its annual meeting of stockholders on November 22, 2024. The
• Transcode Therapeutics Faces Delisting Concerns — 8-K · Sep 27, 2024 Risk: high
  Transcode Therapeutics, Inc. filed an 8-K on September 27, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The
• Transcode Therapeutics to be Acquired by 03 Life Sciences — 8-K · Aug 28, 2024 Risk: medium
  Transcode Therapeutics, Inc. announced on August 28, 2024, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction i
• Transcode Therapeutics Faces Delisting Notice — 8-K · Aug 16, 2024 Risk: high
  Transcode Therapeutics, Inc. filed an 8-K on August 16, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The co
• Transcode Therapeutics Q2 2024 Update — 10-Q · Aug 14, 2024 Risk: medium
  Transcode Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported cash and cash equivalents of $7.27 million. The filing det
• SC 13G Filing — SC 13G · Jul 26, 2024
• Transcode Therapeutics Files 8-K: Material Agreement & Equity Sales — 8-K · Jul 24, 2024 Risk: medium
  Transcode Therapeutics, Inc. announced on July 22, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales o
• Fitzgerald Files SC 13D for Transcode Therapeutics — SC 13D · Jun 21, 2024 Risk: medium
  Thomas A. Fitzgerald filed an SC 13D on June 21, 2024, for Transcode Therapeutics, Inc. The filing indicates a change in beneficial ownership of the company's c
• TransCode Therapeutics Corrects Shareholder Meeting Vote Results — 8-K/A · Jun 14, 2024 Risk: low
  TransCode Therapeutics, Inc. filed an amendment (8-K/A) on June 14, 2024, to its June 13, 2024, 8-K filing. This amendment corrects an error stating that not al
• TransCode Therapeutics Files 8-K on Shareholder Votes — 8-K · Jun 13, 2024 Risk: low
  TransCode Therapeutics, Inc. filed an 8-K on June 13, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specif
• TransCode Therapeutics Regains Nasdaq Listing Compliance — DEFA14A · Jun 10, 2024 Risk: medium
  TransCode Therapeutics, Inc. announced on June 10, 2024, that Nasdaq has determined the company has regained compliance with its continued listing requirements.
• Transcode Therapeutics to be Acquired by 03 Life Sciences — 8-K · Jun 7, 2024 Risk: medium
  Transcode Therapeutics, Inc. announced on June 3, 2024, that it has entered into a definitive agreement to be acquired by 03 Life Sciences. The transaction is e
• 180 Life Sciences to Acquire Transcode Therapeutics — 8-K · May 15, 2024 Risk: medium
  Transcode Therapeutics, Inc. announced on May 15, 2024, that it has entered into a definitive agreement to be acquired by 180 Life Sciences Corp. The transactio

Risk Profile

Risk Assessment: Of RNAZ's 45 recent filings, 6 were flagged as high-risk, 21 as medium-risk, and 18 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.

Financial Highlights

Key financial metrics from Transcode Therapeutics, INC.'s most recent 10-Q filing (Nov 14, 2025):

• Revenue: $0
• Net Income: $(21,217,966)
• EPS: N/A
• Debt-to-Equity: 2.67
• Cash Position: $2,835,916
• Operating Margin: N/A
• Total Assets: $5,226,682
• Total Debt: $832,875

Key Executives

• Philippe P. Calais
• Thomas A. Fitzgerald
• Erik Manting
• Magda Marquet

Industry Context

Transcode Therapeutics operates in the highly competitive biopharmaceutical industry, focusing on oncology. The sector is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Companies like Transcode aim to develop innovative therapies, often through acquisitions or strategic partnerships, to advance promising drug candidates through clinical trials and towards commercialization.

Top Tags

filing (6) · material-agreement (5) · governance (5) · proxy-statement (5) · regulatory (4) · amendment (4) · regulatory-filing (4) · pharmaceuticals (4) · delisting (4) · listing-standards (4)

Key Numbers

• CIK Number: 0001829635 — Identifies Transcode Therapeutics, Inc. in SEC filings.
• Accession Number: 0001104659-26-040171 — Unique identifier for this specific SEC filing.
• Filing Date: 2026-04-07 — Date the 8-K report was officially filed with the SEC.
• Cash at September 30, 2025: $2,835,916 — Decreased from $5,811,064 at December 31, 2024, indicating significant cash burn.
• Net loss for nine months ended September 30, 2025: $(21,217,966) — Increased from $(10,839,013) in 2024, primarily due to warrant liability changes.
• Change in fair value of warrant liabilities: $9,675,797 — Significant expense for the nine months ended September 30, 2025, contributing to net loss.
• Research and development expenses for nine months ended September 30, 2025: $7,946,573 — Increased from $6,067,983 in 2024, reflecting ongoing clinical activities.
• Aggregate purchase price of Series B Preferred Stock by DEFJ, LLC: $25,000,000 — Post-period investment providing crucial liquidity, including $20 million cash and a $5 million promissory note.
• Shares of Common Stock outstanding at November 10, 2025: 916,968 — Reflects recent equity issuances.
• Weighted-average common shares outstanding for three months ended September 30, 2025: 833,683 — Significantly higher than 15,893 shares for the same period in 2024, indicating dilution.
• Net loss per share for three months ended September 30, 2025: $(5.82) — Lower than $(146.06) for the same period in 2024 due to increased share count despite higher net loss.
• SEC File Number: 001-40363 — Identifies the company's filing history with the SEC.
• EIN: 81-1065054 — Employer Identification Number for tax purposes.
• Net loss for six months ended June 30, 2025: $16,361,915 — More than doubled from $8,517,626 in the prior year period.
• Cash at June 30, 2025: $7,374,815 — Increased from $5,811,064 at December 31, 2024, but not sufficient for a full 12 months.

Related Companies

TCOD · TCRT

Frequently Asked Questions